Seal Rock Therapeutics says its novel oral therapy program SRT-055, which aims to treat Parkinson’s disease and other…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
A liquid formulation of levodopa/carbidopa (LD/CD) delivered continuously under the skin via a pump, ND0612 is more effective than…
Analyses done by machine learning of data collected in brain imaging, clinical exams, and laboratory tests can be used to predict…
A novel machine learning algorithm was able to accurately classify people with Parkinson’s disease based on their predicted rate…
Mortality rates appear to be lower among people with Parkinson’s disease psychosis (PDP) being treated with Nuplazid (pimavanserin)…
Older adults with Parkinson’s disease who live in areas with more greenery, parks, or surface water are less likely…
Sleep benefit — a poorly understood phenomenon where people with Parkinson’s disease have fewer symptoms upon waking up —…
An automated algorithm called StimFit may help speed up the time to finding optimal settings of deep brain stimulation…
The European Medicines Agency (EMA) has issued a letter in support of model-based clinical trial simulators for Parkinson’s disease…
Alpha-synuclein clumps’ toxic effects — a hallmark of Parkinson’s disease — are independent of the production of the protein…